Characteristics of patients receiving HLA-identical sibling transplantation for chronic myelogenous leukemia in chronic phase
| Variable . | IFN-α; Dx to BMT ≤1 y (n = 113) . | IFN-α; Dx to BMT >1 y (n = 96) . | Hu; Dx to BMT ≤1 y (n = 463) . | Hu; Dx to BMT >1 y (n = 201) . | No. with Missing Data . | P* . |
|---|---|---|---|---|---|---|
| Median age, y (range) | 36 (11-55) | 40 (10-57) | 36 (11-62) | 35 (11-55) | 0 | .0003 |
| Karnofsky score <90%, n (%) | 12 (11) | 9 (9) | 26 (6) | 21 (11) | 6 | .08 |
| Median WBC at Dx, ×109/L (range) | 142 (5-549) | 122 (5-600) | 152 (1-850) | 116 (13-700) | 44 | .02 |
| Median Hb at Dx, g/L (range) | 120 (71-170) | 120 (42-158) | 120 (24-171) | 120 (50-172) | 135 | .97 |
| Median platelets at Dx, ×109/L (range) | 437 (22-2500) | 431 (2-3025) | 400 (88-5000) | 393 (109-1977) | 111 | .17 |
| Splenomegaly at Dx, n (%) | 61 (58) | 60 (66) | 298 (67) | 119 (62) | 36 | .29 |
| Median WBC preBMT, ×109/L (range) | 8 (3-197) | 9 (2-910) | 1 (1-213) | 12 (3-300) | 5 | .0001 |
| Splenomegaly preBMT, n (%) | 26 (23) | 30 (32) | 139 (31) | 56 (28) | 4 | .38 |
| Splenectomy, n (%) | 1 (1) | 1 (1) | 12 (3) | 2 (1) | 4 | .55 |
| Myelofibrosis preBMT, n (%) | 14 (15) | 20 (24) | 37 (9) | 17 (10) | 129 | .002 |
| Median duration of IFN-α therapy, mo (range) | 3 (1-11) | 2 (1-39) | NA | NA | 65 | .53 |
| Donor/recipient sex, n (%) | 2 | .005 | ||||
| M/M | 49 (43) | 31 (33) | 182 (39) | 64 (32) | ||
| M/F | 25 (22) | 25 (26) | 92 (20) | 36 (18) | ||
| F/M | 20 (18) | 27 (28) | 121 (26) | 46 (23) | ||
| F/F | 19 (17) | 12 (13) | 67 (15) | 54 (27) | ||
| Donor/recipient CMV status, n (%) | 34 | .62 | ||||
| −/− | 31 (29) | 19 (21) | 127 (29) | 45 (23) | ||
| −/+ | 17 (16) | 11 (12) | 70 (16) | 34 (17) | ||
| +/− | 17 (16) | 12 (13) | 60 (14) | 28 (14) | ||
| +/+ | 42 (39) | 48 (53) | 187 (42) | 90 (46) | ||
| Race, n (%) | 4 | .03 | ||||
| White | 101 (89) | 85 (90) | 402 (87) | 161 (80) | ||
| Black | 4 (4) | 5 (5) | 10 (2) | 5 (2) | ||
| Asian | 1 (1) | 2 (2) | 18 (4) | 12 (6) | ||
| Other | 7 (6) | 2 (2) | 30 (7) | 23 (11) | ||
| Conditioning regimen, n (%) | 8 | .16 | ||||
| Bu + Cy ± other | 54 (48) | 57 (60) | 197 (43) | 92 (46) | ||
| TBI + Cy | 37 (33) | 28 (29) | 147 (32) | 65 (33) | ||
| TBI + Cy + other | 12 (11) | 6 (6) | 67 (15) | 26 (13) | ||
| Other | 10 (9) | 4 (4) | 46 (10) | 16 (8) | ||
| GVHD prophylaxis, n (%) | 0 | .001 | ||||
| CsA + other | 21 (19) | 15 (16) | 132 (29) | 30 (15) | ||
| MTX + CsA + other | 92 (81) | 80 (84) | 331 (71) | 171 (85) | ||
| Year of BMT, n (%) | 0 | .001 | ||||
| 1987-88 | 7 (6) | 5 (5) | 90 (19) | 39 (19) | ||
| 1989-90 | 42 (37) | 36 (38) | 162 (35) | 70 (35) | ||
| 1991-92 | 33 (29) | 39 (41) | 143 (31) | 63 (31) | ||
| 1993-94 | 31 (27) | 15 (16) | 68 (15) | 29 (14) |
| Variable . | IFN-α; Dx to BMT ≤1 y (n = 113) . | IFN-α; Dx to BMT >1 y (n = 96) . | Hu; Dx to BMT ≤1 y (n = 463) . | Hu; Dx to BMT >1 y (n = 201) . | No. with Missing Data . | P* . |
|---|---|---|---|---|---|---|
| Median age, y (range) | 36 (11-55) | 40 (10-57) | 36 (11-62) | 35 (11-55) | 0 | .0003 |
| Karnofsky score <90%, n (%) | 12 (11) | 9 (9) | 26 (6) | 21 (11) | 6 | .08 |
| Median WBC at Dx, ×109/L (range) | 142 (5-549) | 122 (5-600) | 152 (1-850) | 116 (13-700) | 44 | .02 |
| Median Hb at Dx, g/L (range) | 120 (71-170) | 120 (42-158) | 120 (24-171) | 120 (50-172) | 135 | .97 |
| Median platelets at Dx, ×109/L (range) | 437 (22-2500) | 431 (2-3025) | 400 (88-5000) | 393 (109-1977) | 111 | .17 |
| Splenomegaly at Dx, n (%) | 61 (58) | 60 (66) | 298 (67) | 119 (62) | 36 | .29 |
| Median WBC preBMT, ×109/L (range) | 8 (3-197) | 9 (2-910) | 1 (1-213) | 12 (3-300) | 5 | .0001 |
| Splenomegaly preBMT, n (%) | 26 (23) | 30 (32) | 139 (31) | 56 (28) | 4 | .38 |
| Splenectomy, n (%) | 1 (1) | 1 (1) | 12 (3) | 2 (1) | 4 | .55 |
| Myelofibrosis preBMT, n (%) | 14 (15) | 20 (24) | 37 (9) | 17 (10) | 129 | .002 |
| Median duration of IFN-α therapy, mo (range) | 3 (1-11) | 2 (1-39) | NA | NA | 65 | .53 |
| Donor/recipient sex, n (%) | 2 | .005 | ||||
| M/M | 49 (43) | 31 (33) | 182 (39) | 64 (32) | ||
| M/F | 25 (22) | 25 (26) | 92 (20) | 36 (18) | ||
| F/M | 20 (18) | 27 (28) | 121 (26) | 46 (23) | ||
| F/F | 19 (17) | 12 (13) | 67 (15) | 54 (27) | ||
| Donor/recipient CMV status, n (%) | 34 | .62 | ||||
| −/− | 31 (29) | 19 (21) | 127 (29) | 45 (23) | ||
| −/+ | 17 (16) | 11 (12) | 70 (16) | 34 (17) | ||
| +/− | 17 (16) | 12 (13) | 60 (14) | 28 (14) | ||
| +/+ | 42 (39) | 48 (53) | 187 (42) | 90 (46) | ||
| Race, n (%) | 4 | .03 | ||||
| White | 101 (89) | 85 (90) | 402 (87) | 161 (80) | ||
| Black | 4 (4) | 5 (5) | 10 (2) | 5 (2) | ||
| Asian | 1 (1) | 2 (2) | 18 (4) | 12 (6) | ||
| Other | 7 (6) | 2 (2) | 30 (7) | 23 (11) | ||
| Conditioning regimen, n (%) | 8 | .16 | ||||
| Bu + Cy ± other | 54 (48) | 57 (60) | 197 (43) | 92 (46) | ||
| TBI + Cy | 37 (33) | 28 (29) | 147 (32) | 65 (33) | ||
| TBI + Cy + other | 12 (11) | 6 (6) | 67 (15) | 26 (13) | ||
| Other | 10 (9) | 4 (4) | 46 (10) | 16 (8) | ||
| GVHD prophylaxis, n (%) | 0 | .001 | ||||
| CsA + other | 21 (19) | 15 (16) | 132 (29) | 30 (15) | ||
| MTX + CsA + other | 92 (81) | 80 (84) | 331 (71) | 171 (85) | ||
| Year of BMT, n (%) | 0 | .001 | ||||
| 1987-88 | 7 (6) | 5 (5) | 90 (19) | 39 (19) | ||
| 1989-90 | 42 (37) | 36 (38) | 162 (35) | 70 (35) | ||
| 1991-92 | 33 (29) | 39 (41) | 143 (31) | 63 (31) | ||
| 1993-94 | 31 (27) | 15 (16) | 68 (15) | 29 (14) |
IFN-α indicates interferon; Dx, diagnosis; BMT, bone marrow transplantation; Hu, hydroxyurea; WBC, white blood cell count; Hb, hemoglobin; NA, not applicable; M, male; F, female; CMV, cytomegalovirus; Bu, busulfan; Cy, cyclophosphamide; TBI, total body irradiation; GVHD, graft-versus-host disease; CsA, cyclosporine; and MTX, methotrexate.
Based on the null hypothesis that distributions in all four groups are the same using χ2 test for categorical variables and the Mann-Whitney test for continuous variables.